ClinicalTrialsFinder
RecruitingPhase 2NCT04135846

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD

Sponsor

Brown University

Enrollment

184 participants

Start Date

Dec 19, 2019

Study Type

INTERVENTIONAL

Conditions

Alcohol Use Disorder (AUD)

Summary

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Doxazosin and a drug called Placebo for people with alcohol use disorder (aud). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDoxazosin

16 mg or maximum tolerated dose (MTD)

DRUGPlacebo

Matching placebo

Locations(1)

Brown University

Providence, Rhode Island, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04135846

Related Trials

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT075595001 location

Study of Tirzepatide for Recovery and Alcohol Use Management

NCT067273312 locations

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

NCT051818911 location

Optimizing Smart Technology for Addiction Recovery

NCT075735401 location

Suvorexant for Treatment of AUD and PTSD

NCT066790622 locations